Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
55.83
+0.04 (0.07%)
At close: Feb 21, 2025, 4:00 PM
56.00
+0.17 (0.30%)
After-hours: Feb 21, 2025, 7:53 PM EST
BMY Employees
Bristol-Myers Squibb Company had 34,100 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
34,100
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,416,422
Profits / Employee
-$262,405
Market Cap
113.30B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 34,100 | 0 | - |
Dec 31, 2023 | 34,100 | -200 | -0.58% |
Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
Dec 31, 2020 | 30,250 | 250 | 0.83% |
Dec 31, 2019 | 30,000 | 6,700 | 28.76% |
Dec 31, 2018 | 23,300 | -400 | -1.69% |
Dec 31, 2017 | 23,700 | -1,300 | -5.20% |
Dec 31, 2016 | 25,000 | 0 | - |
Dec 31, 2015 | 25,000 | 0 | - |
Dec 31, 2014 | 25,000 | -3,000 | -10.71% |
Dec 31, 2013 | 28,000 | 0 | - |
Dec 31, 2012 | 28,000 | 1,000 | 3.70% |
Dec 31, 2011 | 27,000 | 0 | - |
Dec 31, 2010 | 27,000 | -1,000 | -3.57% |
Dec 31, 2009 | 28,000 | -7,000 | -20.00% |
Dec 31, 2008 | 35,000 | -7,000 | -16.67% |
Dec 31, 2007 | 42,000 | -1,000 | -2.33% |
Dec 31, 2006 | 43,000 | 0 | - |
Dec 31, 2005 | 43,000 | 0 | - |
Dec 31, 2004 | 43,000 | -1,000 | -2.27% |
Dec 31, 2003 | 44,000 | 0 | - |
Dec 31, 2002 | 44,000 | -2,000 | -4.35% |
Dec 31, 2001 | 46,000 | 2,000 | 4.55% |
Dec 31, 2000 | 44,000 | -10,500 | -19.27% |
Dec 31, 1999 | 54,500 | -200 | -0.37% |
Dec 31, 1998 | 54,700 | 1,100 | 2.05% |
Dec 31, 1997 | 53,600 | 2,400 | 4.69% |
Dec 31, 1996 | 51,200 | 2,060 | 4.19% |
Dec 31, 1995 | 49,140 | 1,440 | 3.02% |
Dec 31, 1994 | 47,700 | -1,800 | -3.64% |
Dec 31, 1993 | 49,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
BMY News
- 1 day ago - Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success - Seeking Alpha
- 3 days ago - BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing - PRNewsWire
- 4 days ago - Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields - Benzinga
- 4 days ago - Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer - Business Wire
- 7 days ago - Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills - Seeking Alpha
- 7 days ago - New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis - Business Wire
- 9 days ago - Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial - Business Wire
- 12 days ago - What's Going On With Bristol Myers Squibb Stock On Monday? - Benzinga